Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia (CEPHEUS)

AstraZeneca

Status: Completed

Conditions: Dyslipidaemia

Study type: Observational

Funder types: Industry

Identifiers

NCT01221584

NIS-CRU-DUM-2010/1

Details and patient eligibility

About

The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the All-Russian Scientific Cardiology Society guidelines/ the 4th Joint European Task Force guidelines.

Enrollment: 1,000 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject must be 18 years of age or older of either gender or race.
• Subject must provide informed consent and comply with the survey procedures.
• Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

Exclusion criteria

• Subjects who are unwilling or unable to provide informed consent

Trial design

1,000 participants in 1 patient group

1

Description:

Subject 18 years of age or older on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks..